GSK

Greg Field, CEO of Lasso, Named to MM+M's 40 Under 40 List

Retrieved on: 
Monday, December 5, 2022

This year, Greg Field, CEO of Lasso, an IQVIA business, was named to the list for his contributions to the healthcare communications industry.

Key Points: 
  • This year, Greg Field, CEO of Lasso, an IQVIA business, was named to the list for his contributions to the healthcare communications industry.
  • The 40 Under 40 list includes individuals who hail from a range of employers, from pharma and biotech companies and agencies to device manufacturers, analytics firms and health media.
  • "Of course, that makes the 40 Under 40 selection process a challenge but it's one that we embrace.
  • "I'm honored to be spotlighted in this incredible list of healthcare leaders, among so many of our partners and clients," said Greg Field, CEO at Lasso.

AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer

Retrieved on: 
Friday, December 2, 2022

GSK expects to publish full results from the RUBY trial in a medical journal and present at an upcoming scientific meeting.

Key Points: 
  • GSK expects to publish full results from the RUBY trial in a medical journal and present at an upcoming scientific meeting.
  • RUBY is a two-part global, randomised, double-blind, multicentre study of patients with primary advanced or recurrent endometrial cancer.
  • RUBY is part of an international collaboration of European Network of Gynaecological Oncological Trial groups (ENGOT) and the GOG Foundation.
  • AnaptysBio is also developing imsidolimab, our anti-IL-36R antibody in Phase 3 for the treatment of generalized pustular psoriasis, or GPP.

MERGE’s Dr. Kirsten Ambegaokar Named To MM+M’s 40 Under 40 List Chicago

Retrieved on: 
Thursday, December 1, 2022

MERGE , a premium storytelling and technology company, is proud to announce that Kristen Henkins Ambegaokar, PhD, Medical Director, Life Sciences, has been named to MM+Ms fourth class of 40 Under 40 honorees.

Key Points: 
  • MERGE , a premium storytelling and technology company, is proud to announce that Kristen Henkins Ambegaokar, PhD, Medical Director, Life Sciences, has been named to MM+Ms fourth class of 40 Under 40 honorees.
  • (Photo: Business Wire)
    The 40 Under 40 list includes individuals who hail from a range of employers, from pharma and biotech companies and agencies to device manufacturers, analytics firms and health media.
  • Of course, that makes the 40 Under 40 selection process a challenge but its one that we embrace.
  • We are thrilled to have Kristen recognized by MM+M as a 40 under 40 honoree, says Pat McGloin, Chief Client Officer for MERGE.

The Weber Shandwick Collective Launches Business & Society Futures to Advise Clients Across Business Strategy, Stakeholder Expectations and Societal Impact

Retrieved on: 
Thursday, December 1, 2022

NEW YORK, Dec. 1, 2022 /PRNewswire/ -- Today, The Weber Shandwick Collective (TWSC) launched Business & Society Futures, comprised of the Collective's advisory brands, Powell Tate, United Minds, KRC Research and Weber Shandwick's Corporate Affairs, Public Affairs and Social Impact & Sustainability practices. The agency network also announced the creation of The Collective Senior Advisors, a new group of outside senior advisors who will counsel clients on leadership positioning, organizational effectiveness, policy and regulatory complexity, positive societal impact and value creation for all stakeholders. 

Key Points: 
  • - The Collective Senior Advisors, a new group of external senior advisors from business, government, civil society and academia joins Business & Society Futures to advise clients on business strategy, stakeholder insights and leadership positioning
    - New research finds that CEOs & C-suite leaders believe societal issues and stakeholder expectations are now directly connected to commercial performance.
  • NEW YORK, Dec. 1, 2022 /PRNewswire/ -- Today, The Weber Shandwick Collective (TWSC) launched Business & Society Futures, comprised of the Collective's advisory brands, Powell Tate, United Minds, KRC Research and Weber Shandwick's Corporate Affairs, Public Affairs and Social Impact & Sustainability practices.
  • "The formation of Business & Society Futures and the addition of The Collective Senior Advisors enables us to more seamlessly and nimbly provide clients a range of expertise and capabilities related to their company's business performance, stakeholder expectations and societal impact."
  • Business & Society Futures will be led by Chris Deri, Weber Shandwick's Chief Corporate Affairs Officer and President of TWSC's C-suite Advisory Business.

Yolanda Sanchez, ex-GSK R&D Leader, Joins BioSymetrics as Scientific Advisor

Retrieved on: 
Thursday, December 1, 2022

BOSTON and TORONTO, Dec. 1, 2022 /PRNewswire/ -- BioSymetrics, a phenomics-driven AI drug discovery company, announces that Yolanda Sanchez has joined its strategic advisory board earlier this year. Yolanda is a pharmaceutical and biotech industry expert with over 20 years of experience. As an advisor to BioSymetrics, she has been supporting the advancement of the company's target discovery platform and drug discovery programs, and advising on general scientific strategy.

Key Points: 
  • As an advisor to BioSymetrics, she has been supporting the advancement of the company's target discovery platform and drug discovery programs, and advising on general scientific strategy.
  • A strong believer in diversified biological models and data applications to accelerate drug discovery, Yolanda has worked with innovative startups in this space, including BioSymetrics.
  • "Yolanda combines extensive pharmaceutical and biotech industry experience with a passion for new technologies to accelerate drug discovery and development.
  • We are thrilled to work with her as an advisor," said Anthony Iacovone, Co-Founder and CEO, BioSymetrics.

Major Corporations Launch New Coalition to Help End HIV in the United States

Retrieved on: 
Thursday, December 1, 2022

Today on World AIDS Day, the Health Action Alliance and ViiV Healthcare announce the launch of U.S. Business Action to End HIV, a new coalition of businesses committed to accelerating progress to end HIV in the U.S. by 2030.

Key Points: 
  • Today on World AIDS Day, the Health Action Alliance and ViiV Healthcare announce the launch of U.S. Business Action to End HIV, a new coalition of businesses committed to accelerating progress to end HIV in the U.S. by 2030.
  • View the full release here: https://www.businesswire.com/news/home/20221201005283/en/
    The coalition launch is part of the White Houses World AIDS Day commemoration.
  • U.S. Business Action to End HIV formed in response to the National HIV/AIDS Strategy, which seeks to mobilize all sectors of society in a united response.
  • By harnessing the influence and expertise of the private sector, the coalition brings new momentum to an effort once thought impossible to end the HIV epidemic in the U.S. by 2030.

Orchard Therapeutics Announces Swissmedic Validation of the Marketing Authorization Application for Libmeldy (atidarsagene autotemcel)

Retrieved on: 
Thursday, December 1, 2022

The Swiss filing was based on the European Union (EU) MAA for Libmeldy, which was approved by the European Commission in December 2020.

Key Points: 
  • The Swiss filing was based on the European Union (EU) MAA for Libmeldy, which was approved by the European Commission in December 2020.
  • Over time, the nervous system is damaged, leading to neurological problems such as motor, behavioral and cognitive regression, severe spasticity and seizures.
  • For more information about Libmeldy, please see the Summary of Product Characteristics (SmPC) available on the EMA website.
  • At Orchard Therapeutics, our vision is to end the devastation caused by genetic and other severe diseases.

GHO Capital invests in Sapio Sciences, a leading, high growth lab informatics platform company

Retrieved on: 
Thursday, December 1, 2022

The business is optimally positioned in a high growth market where many incumbent solutions are not fit for purpose.

Key Points: 
  • The business is optimally positioned in a high growth market where many incumbent solutions are not fit for purpose.
  • GHOs support and investment will allow Sapio to explore multiple avenues for growth and expansion for the company, product offering and global footprint.
  • The Partners at GHO Capital, said, The trend towards adopting lab informatics solutions is accelerating.
  • Sapio provides LIMS, ELN, and Scientific Data Management Solutions through its flexible, scalable, and easy-to-use Seamless Informatics Platform.

ViiV Healthcare Unveils a New Global Study Revealing Three Quarters of People Believe There Are Still Negative Perceptions When It Comes to People Living With HIV

Retrieved on: 
Thursday, December 1, 2022

Weve come a long way but too many examples persist and we need a unified voice to challenge these.

Key Points: 
  • Weve come a long way but too many examples persist and we need a unified voice to challenge these.
  • HIV in View campaign collaborator and drag superstar Charity Kase says, HIV has changed.
  • Members of the HIV community can lead vibrant, rewarding lives and deserve to live peacefully without fear of judgement.
  • The HIV in View collection is available for free under Shutterstocks standard license to use in projects, campaigns and communications.

Innoviva Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam (SUL-DUR)

Retrieved on: 
Wednesday, November 30, 2022

The Agency is currently planning to hold an advisory committee meeting to discuss this application.

Key Points: 
  • The Agency is currently planning to hold an advisory committee meeting to discuss this application.
  • SUL-DUR also exhibited a favorable safety profile with statistically significant reduction in nephrotoxicity.
  • Carbapenem-resistant and multidrug-resistant Acinetobacter infections are an urgent and emergent threat due to increasing rates of resistance and few viable treatment options.
  • Our focused and dedicated team looks forward to continuing to work with the FDA throughout the priority review process.